Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
125.61 ^USD	-5.60%		-3.15%	+22.98%

Jun. 02	Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95	MT
May. 29	Guardant Health Insider Sold Shares Worth $1,250,836, According to a Recent SEC Filing	MT

Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published on 05/07/2026 at 05:17 pm EDT

S&P Capital IQ

GUARDANT HEALTH, INC.

-5.60%

Guardant Health, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 301.67 million compared to USD 203.47 million a year ago. Net loss was USD 112.08 million compared to USD 95.16 million a year ago.

Basic loss per share from continuing operations was USD 0.85 compared to USD 0.77 a year ago.

Latest news about Guardant Health, Inc.

Jun. 02	Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95	MT
May. 29	Guardant Health Insider Sold Shares Worth $1,250,836, According to a Recent SEC Filing	MT
May. 27	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid S&P 500, Nasdaq Rally, Middle East Peace Optimism	MT
May. 27	Guardant Health Says Shield Blood Test Included in American Cancer Society Guidelines	MT
May. 27	Guardant Health Shield Blood Test Included in Updated American Cancer Society Colorectal Cancer Screening Guidelines	CI
May. 27	Blood test added to US colorectal cancer screening options	RE
May. 26	Guardant Health Insider Sold Shares Worth $2,896,360, According to a Recent SEC Filing	MT
May. 22	Guardant Health Insider Sold Shares Worth $735,049, According to a Recent SEC Filing	MT
May. 22	Guardant Health Insider Sold Shares Worth $23,076,690, According to a Recent SEC Filing	MT
May. 22	Guardant Health Insider Sold Shares Worth $2,130,229, According to a Recent SEC Filing	MT
May. 20	Guardant Health Says US FDA Approved Liquid Biopsy Test	MT
May. 20	Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint	RE
May. 20	Guardant Health Announces Fda Approval Of Guardant360 Liquid Cdx, The Largest Fda-Approved Liquid Biopsy Panel	CI
May. 13	Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing	MT
May. 12	Guardant Health, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM

Chart Guardant Health, Inc.

Duration

Period

GH: Dynamic Chart

Company Profile

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,498

Sector

Medical Equipment, Supplies & Distribution

More about the company